These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 8573668)

  • 1. In vitro contact phase activation with haemodialysis membranes: role of pharmaceutical agents.
    Matata BM; Wark S; Sundaram S; Courtney JM; Gaylor JD; Bowry SK; Vienken J; Lowe GD
    Biomaterials; 1995 Nov; 16(17):1305-12. PubMed ID: 8573668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determination of contact phase activation by the measurement of the activity of supernatant and membrane surface-adsorbed factor XII (FXII): its relevance as a useful parameter for the in vitro assessment of haemodialysis membranes.
    Matata BM; Courtney JM; Sundaram S; Wark S; Bowry SK; Vienken J; Lowe GD
    J Biomed Mater Res; 1996 May; 31(1):63-70. PubMed ID: 8731150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effect of blood purification materials and anticoagulants on the contact activity of factor XI].
    Cheng LP; Sun SD; Yue YL; Huang J
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2005 May; 36(3):411-4. PubMed ID: 15931883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modification of the influence of biomaterials on contact activation.
    Sundaram S; Irvine L; Courtney JM; Lowe GD
    Int J Artif Organs; 1991 Nov; 14(11):729-31. PubMed ID: 1661710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Studies of adsorption, activation, and inhibition of factor XII on immobilized heparin.
    Sanchez J; Elgue G; Riesenfeld J; Olsson P
    Thromb Res; 1998 Jan; 89(1):41-50. PubMed ID: 9610759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Competitive-protein adsorption in contact activation of blood factor XII.
    Zhuo R; Siedlecki CA; Vogler EA
    Biomaterials; 2007 Oct; 28(30):4355-69. PubMed ID: 17644174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibrinolytic properties of activated FXII.
    Braat EA; Dooijewaard G; Rijken DC
    Eur J Biochem; 1999 Aug; 263(3):904-11. PubMed ID: 10469157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential binding of factor XII and activated factor XII to soluble and immobilized fibronectin--localization of the Hep-1/Fib-1 binding site for activated factor XII.
    Schousboe I; Nystrøm BT; Hansen GH
    FEBS J; 2008 Oct; 275(20):5161-72. PubMed ID: 18793325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Binding of activated Factor XII to endothelial cells affects its inactivation by the C1-esterase inhibitor.
    Schousboe I
    Eur J Biochem; 2003 Jan; 270(1):111-8. PubMed ID: 12492481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro investigation of the blood response to medical grade PVC and the effect of heparin on the blood response.
    Lamba NM; Courtney JM; Gaylor JD; Lowe GD
    Biomaterials; 2000 Jan; 21(1):89-96. PubMed ID: 10619682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contact activation of plasmatic coagulation on polymeric membranes measured by the activity of kallikrein in heparinized plasma.
    Groth T; Synowitz J; Malsch G; Richau K; Albrecht W; Lange KP; Paul D
    J Biomater Sci Polym Ed; 1997; 8(10):797-807. PubMed ID: 9297604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The levels of factor XIIa generated in human plasma on an electronegative surface are insensitive to wide variation in the concentration of FXII, prekallikrein, high molecular weight kininogen or FXI.
    Mitropoulos KA
    Thromb Haemost; 1999 Sep; 82(3):1033-40. PubMed ID: 10494760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High affinity binding of factor XIIa to an electronegative surface controls the rates of factor XII and prekallikrein activation in vitro.
    Mitropoulos KA
    Thromb Res; 1999 Apr; 94(2):117-29. PubMed ID: 10230897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factor XII as a Therapeutic Target in Thromboembolic and Inflammatory Diseases.
    Nickel KF; Long AT; Fuchs TA; Butler LM; Renné T
    Arterioscler Thromb Vasc Biol; 2017 Jan; 37(1):13-20. PubMed ID: 27834692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of surface-immobilized heparin on the activation of adsorbed factor XII.
    Elgue G; Sanchez J; Egberg N; Olsson P; Riesenfeld J
    Artif Organs; 1993 Aug; 17(8):721-6. PubMed ID: 8215954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of heparin, heparin plus aprotinin and hirudin on contact activation in a cardiopulmonary bypass model.
    Wendel HP; Heller W; Gallimore MJ
    Immunopharmacology; 1996 May; 32(1-3):57-61. PubMed ID: 8796267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of contact system activation in hemodialyzer-induced thrombogenicity.
    Frank RD; Weber J; Dresbach H; Thelen H; Weiss C; Floege J
    Kidney Int; 2001 Nov; 60(5):1972-81. PubMed ID: 11703617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of different anticoagulants on platelet aggregation in whole blood; a comparison between citrate, low molecular mass heparin and hirudin.
    Wallén NH; Ladjevardi M; Albert J; Bröijersén A
    Thromb Res; 1997 Jul; 87(1):151-7. PubMed ID: 9253810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant hirudin as an anticoagulant during cardiac operations: experiments in a pig model.
    Riess FC; Pötzsch B; Behr I; Jäger K; Rössing R; Bleese N; Schaper W; Müller-Berghaus G
    Eur J Cardiothorac Surg; 1997 Apr; 11(4):739-45. PubMed ID: 9151047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anticoagulation during haemodialysis in patients at high-risk of bleeding.
    Kim YG
    Nephrology (Carlton); 2003 Oct; 8 Suppl():S23-7. PubMed ID: 15012687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.